SCHEMBL10104475

SCHEMBL10104475

COc1c(C)cc(C(C)(C)C)cc1CN(C)CCN(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.41
CYP1A2 P05177 2/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
HIF1A Q16665 1/20 0.40
KDM4E B2RXH2 1/20 0.39
BCHE P06276 1/20 0.33
ACHE P22303 1/20 0.33
MEN1 O00255 1/20 0.33
TNNI3 P19429 1/20 0.33
TNNT2 P45379 1/20 0.33
TNNC1 P63316 1/20 0.33
KMT2A Q03164 1/20 0.33
ALOX15 P16050 1/20 0.32
MAPK1 P28482 1/20 0.32
HTT P42858 1/20 0.32
DRD1 P21728 1/20 0.32
DRD3 P35462 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
CHRM2 P08172 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10104434 0.86 CYP2C19 (0.56) CYP2C19CYP1A2CYP2D6CYP2C9HIF1A
SCHEMBL1404655 0.86 CYP2C19 (0.40) CYP2C19CYP1A2CYP2D6CYP2C9HIF1A
SCHEMBL13130587 0.83 CYP2C19 (0.38) CYP2C19CYP1A2CYP2D6CYP2C9HIF1A
SCHEMBL1404550 0.80 ALDH1A1 (0.39) CYP2C19CYP1A2CYP2D6CYP2C9HIF1A
SCHEMBL5118633 0.80 BCHE (0.39) CYP2C19CYP1A2CYP2D6CYP2C9HIF1A
SCHEMBL10104519 0.74 HTT (0.35) KDM4EMEN1KMT2AHTTDRD1
SCHEMBL13452244 0.74 DHFR (0.41) CYP2C19CYP1A2CYP2D6CYP2C9HTR1D
SCHEMBL12929955 0.73 MAPT (0.43) CYP2C19CYP1A2CYP2D6CYP2C9HIF1A
SCHEMBL19665008 0.72 CYP2C19 (0.38) CYP2C19CYP1A2CYP2D6CYP2C9HIF1A
SCHEMBL10104511 0.72 CYP3A4 (0.42) CYP2C19CYP1A2CYP2D6KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8778929-B2 Substituted heteroaryl inhibitors of B-RAF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-15 US disclosed
US-8653087-B2 Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-02-18 US disclosed
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-04-19 US disclosed
US-20110312939-A1 NEW CHEMICAL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312939-A1 NEW CHEMICAL COMPOUNDS CCNA1, CCNT1, MKI67 CYP2C19 818/4885CYP1A2 174/4885CYP2D6 554/4885
US-20120094975-A1 PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS CCNT1, CCNA1, CCND1 CYP2C19 637/4885CYP1A2 604/4885CYP2D6 470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.